Review of regulatory programs and new opioid technologies in chronic pain management: Balancing the risk of medication abuse with medical need

Journal of Managed Care Pharmacy

Volumn 16, Issue 4, 2010, Pages 276-287

  Fishbain, David ^a   Johnson, Sandra ^b   Webster, Lynn ^c,d   Greene, Laurence ^e   Faysal, Joanne ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c Lifetree Clinical Research and Pain Clinic   (United States)

^d LifeSource Foundation   (United States)

^e PRIME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUROX; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; COL 003; CORTICOSTEROID; CYCLOBENZAPRINE; DULOXETINE; EMBEDA; EXALGO; FLUOXETINE; HYDROCODONE; HYDROMORPHONE; LOCAL ANESTHETIC AGENT; MILNACIPRAN; MORPHINE; MORPHINE SULFATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALTREXONE; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PLACEBO; PREGABALIN; PTI 821; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

BRAIN CORTEX; CHRONIC PAIN; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ABSORPTION; DRUG ABUSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; EUPHORIA; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; NEUROPATHIC PAIN; NOCICEPTION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; RISK; SIDE EFFECT;

EID: 77953296161     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.4.276     Document Type: Note

References (97)

1. National Institutes of Health. NIH guide. New directions in pain research. September 4, 1998. Available at: http://grants.nih.gov/grants/guide/ pa-files/ PA-98-102.html. Accessed April 24, 2010.
2. National Headache Foundation. Headache topic sheet: migraine. 2010. Available at: http://www.headaches.org/education/Headache-Topic-Sheets/ Migraine. Accessed April 24, 2010.
3. National Center for Health Statistics. Health, United States, 2006 with chartbook on trends in the health of Americans. November 2006. Available at: www.cdc.gov/nchs/data/hus/hus06.pdf. Accessed April 24, 2010.
4. National Center for Chronic Disease Prevention and Health Promotion. Arthritis: data and statistics. Available at: http://www.cdc.gov/ARTHRITIS/ data-statistics/arthritis-related-statistics.htm. Accessed April 24, 2010.
5. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25. Available at: http://www3.interscience. wiley.com/cgi-bin/fulltext/117874817/PDFSTART. Accessed April 24, 2010.
6. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35. Available at: http://www3.interscience. wiley.com/cgi-bin/fulltext/117874826/PDFSTART. Accessed April 24, 2010.
7. National Fibromyalgia Association. About fibromyalgia. Available at: http://www.fmaware.org/site/PageServer?pagename=fibromyalgia-affected. Accessed April 24, 2010.
8. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA. 2007;297(3):249-51.
9. Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm. 2009;15(7):556-62. Available at: http://www.amcp.org/ data/jmcp/556-562.pdf.
10. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11(6):469-79. Available at: http://www.amcp.org/data/jmcp/3.pdf.
11. IASP Task Force of Taxonomy. Part III: Pain terms, a current list with definitions and notes on usage. In: Merskey H, Bogbuk N, ed. Classification of Chronic Pain. Seattle, WA: IASP Press; 1994:209-14.
12. Johnson Wright LJ, Afari N, Zautra A. The illness uncertainty concept: a review. Curr Pain Headache Rep. 2009;13(2):133-38.
13. Fishbain DA, Bruns D, Disorbio JM, Lewis JE, Gao J. Exploration of the illness uncertainty concept in acute and chronic pain patients vs community patients. Pain Med. In press.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th ed. Washington, DC: American Psychiatric Association; 2000.
15. Morgan GE Jr, Mikhail MS, Murray MJ. Pain management. In: Morgan GE Jr, Mikhail MS, Murray MJ, eds. Clinical Anesthesiology. New York: McGraw-Hill; 2006:389-412.
16. Strang P, Strang S, Hultborn R, Arnér S. Existential pain - an entity, a provocation, or a challenge? J Pain Symptom Manage. 2004;27(3):241-50.
17. Jage J. Opioid tolerance and dependence - do they matter? Eur J Pain. 2005;9(2):157-62.
18. Wambach S, Rohr P, Häuser W. Abuse of opioid therapy in somatoform pain disorder. A contribution from a psychosomatic/pain therapist point of view to the discussion of the indication of opioids in nonmalignant pain based on 8 cases. Schmerz. 2001;15(4):254-64.
19. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci. 2002;5 Suppl:1062-67.
20. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140(6):441-51. Available at: http://www.annals.org/cgi/reprint/140/6/441.pdf. Accessed April 24, 2010.
21. Woolf CJ, Doubell TP. The pathophysiology of chronic pain - increased sensitivity to low threshold A beta-fibre inputs. Curr Opin Neurobiol. 1994;4(4):525-34.
22. Basbaum AI, Jessel TM. The perception of pain. In: Kandel ER, Schwatrz JH, Jessel TM, eds. Principles of Neural Science. New York: McGraw-Hill; 2000:472-91.
23. Baron R. Mechanisms of disease: neuropathic pain - a clinical perspective. Nat Clin Pract Neurol. 2006;2(2):95-106. Available at: http://www. nature.com/nrneurol/journal/v2/n2/pdf/ncpneuro0113.pdf. Accessed April 24, 2010.
24. Chong MS, Bajwa ZH. Diagnosis and treatment of neuropathic pain. J Pain Symptom Manage. 2003;25(5 Suppl):S4-S11.
25. Woolf CJ, Ma Q. Nociceptors - noxious stimulus detectors. Neuron. 2007;55(3):353-64. Available at: http://www.sciencedirect.com/science?- ob=MImg&-imagekey=B6WSS-4PB1JGW-5-1&-cdi=7054&- user=4420034&- pii=S0896627307005375&-orig=search&- coverDate=08%2F02%2F2007&-sk= 999449996&view=c&wchp=dGLbVlzzSkWb& md5= 39e54a84638f17b918dbf03f722cb00e&ie=/sdarticle.pdf. Accessed April 24, 2010.
26. Lynch ME. The pharmacotherapy of chronic pain. Rheum Dis Clin North Am. 2008;34(2):369-85.
27. Messing RO. Nervous system disorders. In: McPhee SJ, Ganong WF, eds. Pathophysiology of Disease. New York: McGraw-Hill; 2006:144-87.
28. Kennedy JD. Neuropathic pain: molecular complexity underlies continuing unmet medical need. J Med Chem. 2007;50(11):2547-56.
29. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum. 1990;33(2):160-72.
30. Mannion RJ, Woolf CJ. Pain mechanisms and management: a central perspective. Clin J Pain. 2000;16(3 Suppl):S144-S56.
31. Fields HL, Martin JB. Pain: pathophysiology and management. In: Fauci AS, Braunweld E, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2008.
32. Petersen-Felix S, Curatolo M. Neuroplasticity - important factor in acute and chronic pain. Swiss Med Wkly. 2002;132(21-22):273-78. Available at: http://www.smw.ch/docs/pdf200x/2002/21/smw-09913.pdf. Accessed April 24, 2010.
33. Blackburn-Munro G, Blackburn-Munro RE. Chronic pain, chronic stress and depression: coincidence or consequence? J Neuroendocrinol. 2001;13(12):1009-23.
34. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288(5472):1765-69.
35. Fishbain DA. Polypharmacy treatment approaches to the psychiatric and somatic comorbidities found in patients with chronic pain. Am J Phys Med Rehabil. 2005;84(3 Suppl):S56-S63.
36. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444-59. (Pubitemid 351722518)
37. Gallagher RM. Rational integration of pharmacologic, behavioral, and rehabilitation strategies in the treatment of chronic pain. Am J Phys Med Rehabil. 2005;84(3 Suppl):S64-S76.
38. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292(19):2388-95. Available at: http://jama.ama-assn. org/cgi/reprint/292/19/2388. Accessed April 24, 2010.
39. Phillips KA. Pain disorder (somatoform pain disorder). Merck.com. June 2008. Available at: http://www.merck.com/mmpe/sec15/ch204/ch204f. html#sec15-ch204-ch204f-807. Accessed April 25, 2010.
40. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and non-medical use of opioids. Pain Physician. 2008;11(2 Suppl):S63-S88. Available at: http://www.painphysicianjournal.com/2008/march/2008;11;S63-S88.pdf. Accessed April 24, 2010. (Pubitemid 351682079)
41. Drug Enforcement Administration Office of Diversion Control. ARCOS: retail drug summary 1997-2006. Available at: http://www.deadiversion. usdoj.gov/arcos/retail-drug-summary/index.html. Accessed April 25, 2010.
42. Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain. May 2004. Available at: http://www.fsmb.org/pdf/2004-grpol-Controlled-Substances. pdf. Accessed April 25, 2010.
43. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health: National Findings. (Office of Applied Studies, NSDUH Series H-36, DHHS Publication No. SMA 09-4434). Rockville, MD. 2009. Available at: www.oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.pdf. Accessed April 25, 2010.
44. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2006: national estimates of drug-related emergency department visits. (Office of Applied Studies, DAWN Series D-30, DHHS Publication No. SMA 08-4339). Rockville, MD. August 2008. Available at: http://www.odmhsas.org/resourcecenter/ ResourceCenter/ Publications/Current/2005.pdf. Accessed April 29, 2010.
45. Hughes AA, Bogdan GM, Dart RC. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison. Clin Toxicol (Phila). 2007;45(2):144-51.
46. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. September 2009. Available at: http://www.cdc.gov/nchs/data/databriefs/db22.pdf. Accessed April 25, 2010.
47. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use, 1997-2007. Volume I: Secondary school students. National Institute on Drug Abuse. September 2008. Available at: http://monitoringthefuture.org/pubs/monographs/vol1-2007. pdf. Accessed April 25, 2010.
48. Johnson SH. Regulatory and compliance aspects of pain management in managed care. Presented at: Managed Care Workgroup on Pain Management; May 1, 2009; Miami, FL.
49. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007;8(2):171-83.
50. National Forensic Laboratory Information System (NFLIS). Year 2008 Annual Report. Springfield, VA: Drug Enforcement Administration Office of Diversion Control; July 2009. Available at: http://www.deadiversion.usdoj. gov/nflis/2008annual-rpt.pdf. Accessed April 25, 2010.
51. Busko M. Internet trafficking of controlled prescription drugs remains extensive. July 18, 2008. Medscape Medical News. Available at: http://www. medscape.com/viewarticle/577728. Accessed April 25, 2010.
52. Weissman DE, Haddox JD. Opioid pseudoaddiction - an iatrogenic syndrome. Pain. 1989;36(3):363-66.
53. U.S. Food and Drug Administration. About FDA: centers & offices. Available at: http://www.fda.gov/AboutFDA/CentersOffices/default.htm. Accessed April 25, 2010.
54. U.S. Drug Enforcement Administration. DEA mission statement. Available at: http://www.justice.gov/dea/agency/mission.htm. Accessed April 25, 2010.
55. Substance Abuse and Mental Health Services Administration. About us: agency overview. Available at: http://www.samhsa.gov/About/background. aspx. Accessed April 25, 2010.
56. National Institute on Drug Abuse. About NIDA: mission. Available at: http://www.drugabuse.gov/about/aboutnida.html. Accessed April 25, 2010.
57. Office of National Drug Control Policy. About. Available at: http://www. whitehousedrugpolicy.gov/about/index.html. Accessed April 25, 2010.
58. Johnson SH. Disciplinary actions and pain relief: analysis of the Pain Relief Act. J Law Med Ethics. 1996;24(4):319-27.
59. Joranson DE, Gilson AM, Dahl JL, Haddox JD. Pain management, controlled substances, and state medical board policy: a decade of change. J Pain Symptom Manage. 2002;23(2):138-47.
60. Federation of State Medical Boards. FSMB model policy. Available at: http://www.fsmb.org/grpol-pain-policy-resource-center.html. Accessed April 25, 2010.
61. U.S. Drug Enforcement Administration. Title 21 - food and drugs. Chapter 13: Drug abuse prevention and control. Available at: http://www. justice.gov/dea/pubs/csa.html. Accessed April 25, 2010.
62. U.S. Drug Enforcement Administration. DEA congressional testimony. Status of the efforts of the FDA and DEA in regulating Schedule II prescription painkillers, specifically OxyContin and other opioid analgesics. September 13, 2005. Available at: http://www.justice.gov/dea/pubs/cngrtest/ ct091305.html. Accessed April 25, 2010.
63. U.S. Food and Drug Administration. Questions and answers on the federal register notice on drugs and biological products deemed to have risk evaluation and mitigation strategies. March 27, 2008. Available at: http://www.fda.gov/ RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/ SignificantAmendments totheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/ ucm095439.htm. Accessed April 25, 2010.
64. Young D. Pharmacists, physicians lack training to identify drug diversion, report says. American Society of Health-System Pharmacists. July 7, 2005. Available at: http://www.ashp.org/import/news/ HealthSystemPharmacyNews/ newsarticle.aspx?id=1925. Accessed April 29, 2010.
65. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-30.
66. Adler RH, et al. How not to miss a somatic needle in the haystack of chronic pain. J Psychosom Res. 1997;42(5):499-505.
67. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360-72.
68. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-42.
69. Coambs RB, Jarry JL, Santhiapillai AC, Abrahamsohn RV, et al. The SISAP: a new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain within general medical practice. Pain Res Manage. 1996;1(3):155-62. Available at: http://www.pulsus. com/journals/abstract.jsp?jnlKy=7&atlKy=2908&isuKy=520&isArt= t&HCty pe=Consumer. Accessed April 25, 2010.
70. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671-81.
71. Passik S, Portenoy RK, Ricketts PL. Substance abuse among cancer patients, part 1: prevalence and diagnosis. Oncology (Williston Park). 1998;12(4):517-21, 524.
72. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130(1-2):144-56.
73. Passik SD, Kirsh KL, Whitcomb L, et al. Monitoring outcomes during long-term opioid therapy for noncancer pain: results with the pain assessment and documentation tool. J Opioid Manag. 2005;1(5):257-66.
74. U.S. General Accountability Office. Prescription drugs: state monitoring programs provide useful tool to reduce diversion. May 2002. Available at: http://www.gao.gov/new.items/d02634.pdf. Accessed April 25, 2010.
75. U.S. Department of Justice. National Drug Intelligence Center. National prescription drug threat assessment 2009. Available at: http://www.usdoj. gov/ndic/pubs33/33775/33775p.pdf. Accessed April 25, 2010.
76. Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain management. Pain Physician. 2009;12(3):507-15.
77. Simeone R, Holland L. An evaluation of prescription drug monitoring programs. September 1, 2006. Available at: http://www.simeoneassociates. com/simeone3.pdf. Accessed April 25, 2010.
78. Lambert D. Impact evaluation of Maine's prescription drug monitoring program. March 2007. Available at: http://www.maine.gov/dhhs/osa/data/ pmp/files/Reports/ME-PMP-IMPACT-EVAL-2007.pdf. Accessed April 25, 2010.
79. IJIS Institute. Prescription monitoring program (PMP). Available at: http://www.ijis.org/-programs/pdmp.html. Accessed April 25, 2010.
80. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med. 2009;10(Suppl 2):S124-S33.
81. U.S. Food and Drug Administration. Advisory committee meeting: background package (Acurox, NDA 22-451). April 22, 2010. Available at: http:// www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM209141. pdf. Accessed April 25, 2010.
82. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11-18.
83. U.S. Food and Drug Administration. NDA 022272 approval letter. OxyContin (oxycodone hydrochloride controlled-release) tablets. April 5, 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ appletter/2010/022272s000ltr. pdf. Accessed April 25, 2010.
84. U.S. Food and Drug Administration. NDA 021217 approval letter. Exalgo (hydromorphone extended-release) tablets. March 1, 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ appletter/2010/021217s000ltr.pdf. Accessed April 25, 2010.
85. U.S. Food and Drug Administration. NDA 22-321 approval letter. EMBEDA (morphine sulfate and naltrexone hydrochloride extended-release) capsules. August 13, 2009. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/appletter/2009/022321s000ltr.pdf. Accessed April 25, 2010.
86. Alpharma Pharmaceuticals. ALO-01 (Morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. NDA 22-32. November 14, 2008. Available at: http://www.fda.gov/ohrms/dockets/AC/08/briefing/2008- 4395b2-02-ALPHARMA.pdf. Accessed April 25, 2010.
87. U.S. Food and Drug Administration. Final minutes: joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. November 14, 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4395m2-finalrevised. pdf. Accessed April 25, 2010.
88. Acura Pharmaceuticals. Acurox tablets. Available at: http://acurapharm. com/products/acurox-tablets. Accessed April 25, 2010.
89. Acura Pharmaceuticals. Aversion technology. Available at: http://acurapharm. com/research-development/aversion-technology. Accessed April 25, 2010.
90. Jasinski DR. Evaluation for flushing, safety and tolerability of niacin (N) in combination with 40 mg of oxycodone. Available at: http://acurapharm. com/investors/presentations-webcasts. Accessed April 25, 2010.
91. King Pharmaceuticals. Acura Pharmaceuticals and King Pharmaceuticals provide update on FDA advisory committee meeting for ACUROX. April 22, 2010. Available at: http://www.kingpharm.com/Investors/News-Details. cfm?news-item-id=552. Accessed April 25, 2010.
92. Pain Therapeutics, Inc. NDA 22-324. Remoxy XRT (oxycodone controlled- release) capsules. Advisory committee briefing materials. October 12, 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008- 4395b1-02-PAIN.pdf. Accessed April 25, 2010.
93. Friedmann N, de Kater AW, Butera PG, Webster LR, Radcliffe S, Langford RM. A novel, long-acting oxycodone formulation deters abuse in humans. Presented at: 3rd International Congress World Institute of Pain; September 2004; Barcelona, Spain.
94. Gilderman L, Butera PG, Gilmore D, Moran LV, Friedmann N. Remoxy: a new opioid drug with effective analgesia and abuse-resistance. Presented at: 25th Annual Meeting of the American Pain Society; May 2006; San Antonio, TX.
95. Fleming A, Noonan P, Wheeler A. Abuse-deterrent properties and pharmacokinetics of a novel sustained release formulation of oxycodone for the treatment of moderate to severe pain. J Pain. 2008;9(Suppl 4):46.
96. Medical News Today. Pain therapeutics receives complete response letter from FDA for REMOXY(R). December 12, 2008. Available at: http://www. medicalnewstoday.com/articles/132740.php. Accessed April 25, 2010.
97. Collegium Pharmaceutical, Inc. Collegium Pharmaceutical Inc. announces submission of a request for special protocol assessment to FDA for pivotal trial for tamper resistant, extended release opioid (COL-003). June 10, 2009. Available at: http://www.collegiumpharma.com/news/20090610.html. Accessed April 25, 2010.